AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
oxandrolone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anabolic steroids | 2011 | 53-39-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic hormone with anabolic and androgenic properties.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 97 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 17 | |||
| kinase-selectivity-class | EIF2AK3 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 21, 1964 | FDA | CREALTA PHARMS LLC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Testicular atrophy | 69.10 | 42.66 | 9 | 403 | 407 | 110588480 |
| Polycythaemia | 64.01 | 42.66 | 11 | 401 | 3264 | 110585623 |
| Cardiac death | 63.80 | 42.66 | 10 | 402 | 1686 | 110587201 |
| Muscle mass | 59.28 | 42.66 | 8 | 404 | 475 | 110588412 |
| Drug abuse | 56.34 | 42.66 | 22 | 390 | 177389 | 110411498 |
| Left ventricular hypertrophy | 43.29 | 42.66 | 10 | 402 | 13234 | 110575653 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A14AA08 | ALIMENTARY TRACT AND METABOLISM ANABOLIC AGENTS FOR SYSTEMIC USE ANABOLIC STEROIDS Androstan derivatives |
| MeSH PA | D000728 | Androgens |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D045930 | Anabolic Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:36413 | anabolic agent |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:50113 | androgen |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
A14AA Androstan derivatives 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Catabolic Process | indication | ||
| Turner syndrome | off-label use | 38804009 | DOID:3491 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Nephrotic syndrome | contraindication | 52254009 | DOID:1184 |
| Peliosis hepatis | contraindication | 58008004 | DOID:914 |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Cholestatic hepatitis | contraindication | 95556007 | |
| Neoplasm of liver | contraindication | 126851005 | DOID:3571 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Hypoalphalipoproteinemia | contraindication | 190785000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | AGONIST | IC50 | 9.09 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018126 | VUID |
| N0000146464 | NUI |
| D00462 | KEGG_DRUG |
| 4018126 | VANDF |
| C0029995 | UMLSCUI |
| CHEBI:7820 | CHEBI |
| CHEMBL1200436 | ChEMBL_ID |
| DB00621 | DRUGBANK_ID |
| D010074 | MESH_DESCRIPTOR_UI |
| 5878 | PUBCHEM_CID |
| 7092 | IUPHAR_LIGAND_ID |
| 1325 | INN_ID |
| 7H6TM3CT4L | UNII |
| 224933 | RXNORM |
| 4491 | MMSL |
| 5209 | MMSL |
| 91416 | MMSL |
| d00566 | MMSL |
| 001258 | NDDF |
| 126128007 | SNOMEDCT_US |
| 2679000 | SNOMEDCT_US |
| 7H6TM3CT4L | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Oxandrolone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-301 | TABLET | 2.50 mg | ORAL | ANDA | 20 sections |
| Oxandrolone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-302 | TABLET | 10 mg | ORAL | ANDA | 20 sections |